Diffused primary cutaneous lymphoma of large B cells, leg type - quick evolution and unfavorable outcome: case report
DOI:
https://doi.org/10.11606/issn.1679-9836.v101i4e-175074Keywords:
Lymphoma, Primary cutaneous lymphoma, Cutaneous B-cell lymphoma, DermatologyAbstract
Primary cutaneous lymphomas are the second most common form of extranodal lymphomas; with B cell lymphomas (CBCLs) representing 20 to 30% of cases. Diffuse cutaneous large B cell lymphoma, leg type (PCDLBCL-LT), represents the most aggressive type of CBCLs. In most cases, the clinical presentation is characterized by solitary plaques or tumors, sometimes ulcerated, on one or both legs, of rapid growth. The diagnosis is confirmed through histopathological and immunohistochemistry studies. Treatment is carried out through chemotherapy and its prognosis is reserved with a 50% to 60% survival in 5 years. The objective of this work is to report a case of diffuse primary B-cell cutaneous lymphoma, leg type in a 75-year-old male patient with a classic clinical presentation and unfavorable outcome, to perform a literary review from 2010 to 2020 in the PUBMED database on the subject, given its rarity and unique aggressiveness. The data was obtained by reviewing the medical record, photographic record and literature review. For all this, it is possible to conclude the importance of multidisciplinary studies, involving dermatologists, hematologists, oncologists and pathologists so that the diagnosis and treatment are instituted as early as possible, given the rarity and aggressiveness of the PCDLBCL-LT.
Downloads
References
Willemze R. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85. https://doi.org/10.1182/blood-2004-09-3502
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-14. doi: https://doi.org/10.1182/blood-2018-11-881268
Kempf W, Kazakov DV, Mitteldorf C. Cutaneous lymphomas. Am J Dermatopathol. 2014;36(3):197-10. https://doi.org/10.1097/DAD.0b013e318289b20e
Moricz CZM de, Sanches Jr. JA. Processos linfoproliferativos da pele: Parte 1 - Linfomas cutâneos de células B. An Bras Dermatol. 2005;80(5):461-71. https://doi.org/10.1590/S0365-05962005000600003
Belda Junior W, Chiacchio N di, Criado PR. Tratado de dermatologia. In: Miyashiro D, Martins JC, Libonatti SPT, Etto LY, Eris APM, Inaoka RJ, Almeida MSS, Chauffaille MLLF, Baiocchi OC, Sanches Junior JA. Linfomas, leucemias e pseudolinfomas. 3ª ed. Rio de Janeiro: Atheneu; 2018. p.2341-90.
Ansell SM. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(7):771-9. https://doi.org/10.1002/ajh.23750
Groves FD, Linet MS, Travis LB, Devesa SS. Cancer Surveillance Series: Non-Hodgkin’s Lymphoma Incidence by Histologic Subtype in the United States From 1978 Through 1995. JNCI J Nat Cancer Inst. 2000;92(15):1240-51. https://doi.org/10.1093/jnci/92.15.1240
Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol. 1999;26(3):276-89.
Heald PW, Edelson RL. Cutaneous T-cell lymphomas. In: Freedberg IM, Eisen AZ, Wolff K, et al. Fitzpatrick’s: dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1227-50.
Kempf W, Zimmermann A, Mitteldorf C. Cutaneous lymphomas—an update 2019. Hematol Oncol. 2019;37(S1):43-7. https://doi.org/10.1002/hon.2584
Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell Lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535-41. http://dx.doi.org/10.1053/j.semdp.2016.11.006
Hope CB, Pincus LB. Primary cutaneous B-cell lymphomas with large cell predominance–primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. Semin Diagn Pathol. 2017;34(1):85-98. doi: https://doi.org/10.1053/j.semdp.2016.11.006
Graham PM, Richardson AS, Schapiro BL, Saunders MD, Stewart DM. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response. JAAD Case Reports. 2018 May;4(4):305-9. https://doi.org/10.1016/j.jdcr.2017.10.012
Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type. Arch Dermatol. 2007;143(9):1144-50. https://doi.org/10.1001/archderm.143.9.1144
Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150(11):1173-9. doi: https://doi.org/10.1001/jamadermatol.2014.821
Jia J, Li W, Zheng Y. Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery. Medicine. 2017;96(8):e6161. http://dx.doi.org/10.1097/MD.0000000000006161
Marrero-Alemán G, Montenegro-Dámaso T, Peñate Y. Primary cutaneous diffuse large B-cell lymphoma, leg type, with spontaneous regression after biopsy. Am J Dermatopathol. 2017;39(10):785-7. doi: http://dx.doi.org/10.1097/DAD.0000000000000874
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Fernanda Blasques de Faria, Isabela Espagolla Santos, Amilcar Castro de Mattos, Elaine Cristina Faria Abrahao Machado, Livia Matida Gontijo
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
